SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 177.42 |
| Enterprise Value ($M) | 43.90 |
| Book Value ($M) | 469.72 |
| Book Value / Share | 10.14 |
| Price / Book | 0.38 |
| NCAV ($M) | 286.56 |
| NCAV / Share | 6.19 |
| Price / NCAV | 0.62 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.36 |
| Return on Assets (ROA) | -0.28 |
| Return on Equity (ROE) | -0.29 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 12.36 |
| Current Ratio | 12.36 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 332.57 |
| Assets | 515.73 |
| Liabilities | 46.01 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.04 |
| Operating Income | -187.84 |
| Net Income | -160.87 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -134.59 |
| Cash from Investing | -302.44 |
| Cash from Financing | 337.25 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 1.50 | -77.05 | |
| 13G/A | Biotechnology Value Fund L P | 9.99 | -4.17 | |
| 13G/A | BlackRock, Inc. | 7.80 | -27.18 | |
| 13G/A | Ra Capital Management, L.p. | 9.90 | -10.46 | |
| 13G/A | Deep Track Capital, LP | 1.32 | -85.11 | |
| 13G/A | Janus Henderson Group Plc | 4.90 | -28.21 | |
| 13G/A | Goldman Sachs Group Inc | 9.60 | 23.15 | |
| 13G/A | Viking Global Investors Lp | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 5.32 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 32,222 | 225,441 | 14.29 | |
| 43,591 | 295,473 | 14.75 | |
| 40,348 | 280,163 | 14.40 | |
| 65,012 | 369,019 | 17.62 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ERAS – Erasca, Inc. | EWTX – Edgewise Therapeutics, Inc. |
| EXEL – Exelixis, Inc. | FGEN – FibroGen, Inc. |
| GBIO – Generation Bio Co. |
Financial data and stock pages provided by
Fintel.io